Stock Price Forecast

March 14, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Liquidia Corp chart...

About the Company

liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.

CEO

Neal Fowler

Exchange

NASDAQ

Website

http://liquidia.com/

$60M

Total Revenue

78

Employees

$1B

Market Capitalization

-16.45

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $LQDA News

Liquidia Corporation (NASDAQ:LQDA) Q4 2023 Earnings Call Transcript

2d ago, source: Yahoo Finance

Liquidia Corporation (NASDAQ:LQDA) Q4 2023 Earnings Call Transcript March 13, 2024 Liquidia Corporation misses on earnings ...

Liquidia Corp (LQDA) Reports Full Year 2023 Financial Results

5d ago, source:

Revenue: Increased to $17.5 million for the year ended December 31, 2023, up from $15.9 million in the previous year. Net ...

Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update

5d ago, source:

Preparing to launch YUTREPIA™ (treprostinil) inhalation powder upon final FDA approvalFederal Circuit rejected request by United Therapeutics for ...

Unveiling 6 Analyst Insights On Liquidia

5d ago, source:

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.0, with a high ...

UPDATE 2-United Therapeutics files litigation with FDA over rival Liquidia's drug application

26d ago, source: Hosted on MSN

Feb 21 (Reuters) - United Therapeutics said on Wednesday it has filed a case with the U.S. FDA, alleging that due procedure was not followed in allowing rival Liquidia Corp's application for a ...

Q4 2023 Liquidia Corp Earnings Call

5d ago, source:

Matt Kaplan; Analyst; Ladenburg Thalmann Kambiz Pashneh-Tala Yazdi; Analyst; Jefferies ...

Liquidia Corporation Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

28d ago, source: ADVFN

Liquidia Corporation (NASDAQ: LQDA) today announced that, in connection with the previously announced appointment of Rajeev Saggar, M.D., Liquidia’s new Chief Medical Officer, it has agreed to ...

Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update

5d ago, source: Morningstar

Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the full year ended December 31, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss ...

Liquidia Corporation (LQDA) Q4 2023 Earnings Call Transcript

5d ago, source: Seeking Alpha

Good morning, and welcome everyone to the Liquidia Corporation Full-Year 2023 Financial Results and Corporate Update Conference Call. My name is Michelle, and I will be your conference operator today.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...